AtbFinder Diagnostic Test System Improves Optimal Selection of Antibiotic Therapy in Persons with Cystic Fibrosis

Tetz, George; Kardava, K; Vecherkovskaya, Maria; Hahn, Andrea; Tsifansky, Michael D.; Koumbourlis, Anastassios C.; Tetz, Victor

doi:10.1128/jcm.01558-22

Cited by 2 publications

(1 citation statement)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…aeruginosa, a decrease in the number of pulmonary exacerbations, and an increase in lung function (73).…”

Section: Alternative Methods For Susceptibility Testingmentioning

confidence: 96%

Biofilm antimicrobial susceptibility testing: where are we and where could we be going?

Coenye

2023

Clin Microbiol Rev

View full text Add to dashboard Cite

SUMMARY Our knowledge about the fundamental aspects of biofilm biology, including the mechanisms behind the reduced antimicrobial susceptibility of biofilms, has increased drastically over the last decades. However, this knowledge has so far not been translated into major changes in clinical practice. While the biofilm concept is increasingly on the radar of clinical microbiologists, physicians, and healthcare professionals in general, the standardized tools to study biofilms in the clinical microbiology laboratory are still lacking; one area in which this is particularly obvious is that of antimicrobial susceptibility testing (AST). It is generally accepted that the biofilm lifestyle has a tremendous impact on antibiotic susceptibility, yet AST is typically still carried out with planktonic cells. On top of that, the microenvironment at the site of infection is an important driver for microbial physiology and hence susceptibility; but this is poorly reflected in current AST methods. The goal of this review is to provide an overview of the state of the art concerning biofilm AST and highlight the knowledge gaps in this area. Subsequently, potential ways to improve biofilm-based AST will be discussed. Finally, bottlenecks currently preventing the use of biofilm AST in clinical practice, as well as the steps needed to get past these bottlenecks, will be discussed.

show abstract

“…aeruginosa, a decrease in the number of pulmonary exacerbations, and an increase in lung function (73).…”

Section: Alternative Methods For Susceptibility Testingmentioning

confidence: 96%

Biofilm antimicrobial susceptibility testing: where are we and where could we be going?

Coenye

2023

Clin Microbiol Rev

View full text Add to dashboard Cite

show abstract

New Strategies for Addressing Antibiotic Resistance Offer Promise, but Time is Running Out

Mertz

2023

IEEE Pulse

View full text Add to dashboard Cite

AtbFinder Diagnostic Test System Improves Optimal Selection of Antibiotic Therapy in Persons with Cystic Fibrosis

Cited by 2 publications

References 55 publications

Biofilm antimicrobial susceptibility testing: where are we and where could we be going?

Biofilm antimicrobial susceptibility testing: where are we and where could we be going?

New Strategies for Addressing Antibiotic Resistance Offer Promise, but Time is Running Out

Contact Info

Product

Resources

About